{"organizations": [], "uuid": "e2e9b685b3af3926dd30566d365bd1c33b34d092", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/7", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/05/08/globe-newswire-xortx-appoints-chairman.html", "country": "US", "domain_rank": 767, "title": "XORTX Appoints Chairman", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-08T15:00:00.000+03:00", "replies_count": 0, "uuid": "e2e9b685b3af3926dd30566d365bd1c33b34d092"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/05/08/globe-newswire-xortx-appoints-chairman.html", "ord_in_thread": 0, "title": "XORTX Appoints Chairman", "locations": [], "entities": {"persons": [{"name": "bruce", "sentiment": "none"}, {"name": "xortx", "sentiment": "none"}, {"name": "bruce rowlands", "sentiment": "none"}, {"name": "allen davidoff", "sentiment": "none"}], "locations": [{"name": "calgary", "sentiment": "none"}, {"name": "alberta", "sentiment": "none"}, {"name": "canada", "sentiment": "none"}], "organizations": [{"name": "xortx therapeutics inc.", "sentiment": "negative"}, {"name": "nasdaq", "sentiment": "none"}, {"name": "tsx venture", "sentiment": "none"}, {"name": "xortx", "sentiment": "none"}, {"name": "tsx", "sentiment": "none"}, {"name": "aptose biosciences inc.", "sentiment": "none"}, {"name": "lorus therapeutics", "sentiment": "none"}, {"name": "dominick & dominick securities canada", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "CALGARY, Alberta, XORTX Therapeutics Inc. (\" XORTX \" or the “ Company ”) (CSE:XRX), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the appointment of Bruce Rowlands, a director of XORTX as Chairman of the Board of Directors.\nBruce Rowlands has extensive experience in the life sciences industry in Canada through his long association with Lorus Therapeutics, a leading Canadian biotechnology company, where he acted as a consultant, banker and senior executive during its early drug development years. Lorus Therapeutics, now Aptose Biosciences Inc., is dual-listed on the TSX and NASDAQ exchanges. Bruce’s involvement in the Canadian life sciences industry coupled with his investment banking experience as Vice President and Director of Dominick & Dominick Securities Canada and his corporate governance knowledge gained through a decade of leading a TSX Venture listed company will be valuable in leading the Board of Directors of XORTX.\nDr. Allen Davidoff, XORTX’s founder and CEO stated, “Bruce Rowlands has been an excellent director and supporter of XORTX for several years and expanding his role with XORTX is a natural transition. This expanded role will permit him to bring his broad capital markets and extensive pharmaceutical industry talents to the benefit of the XORTX. I look forward to working with Bruce to grow the Company and increase the focus on future value creation.\"\nAbout XORTX Therapeutics Inc.\nXORTX Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease. XORTX has lead programs to develop treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease. Secondary programs focus on developing therapies for health consequences that accompany pre-diabetes, diabetes and cardiovascular disease. Additional information on XORTX Therapeutics is available at www.xortx.com .\nFor further information, please contact: Erik Matthews, Corporate Communications & Investor Relations\n+1-747-203-5240 or erik@xortx.com / ray@xortx.com\nThe CSE has neither approved nor disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.\nSource:XORTX Therapeutics Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=UI_AMlxkENJeYvDXPXotYLXtMgxxpN6q_POsuiLt7qxAVswQVQvmBBZRUceYryz1vpUl6WVPiva4eZZk--fsqQ==", "https://www.globenewswire.com/NewsRoom/AttachmentNg/70ad867b-c103-4be6-892c-6d104c93f520", "https://www.globenewswire.com/Tracker?data=rwQRfkLIHWinjgEYC6gijL1WJDXeSNwKYTCWrBzkNHAPPVQKKhlDs1yWxRdn8Z7IUYFmgOsgsuDtMF54rI6-rA==", "https://www.globenewswire.com/Tracker?data=ssNOheFlcL_NmNk6tnqC74D_3ZzM463gaGHfcd7DvyvRxzVwhxKQJvjOTnr3b3bGmUeZZQ_pWDnEk1DsYtwLMw=="], "published": "2018-05-08T15:00:00.000+03:00", "crawled": "2018-05-08T15:33:11.002+03:00", "highlightTitle": ""}